Replies to post #247482 on Amarin Corp Plc (AMRN)

[Babr]

Sharin I have not seen the label yet all I know is that, they can market it as an add-on to Statin therapy for cardiovascular Indication to lower LDL, and you know how easy it is to sell a drug to these doctors especially cardiologist for lowering LDL to Zero!

[bfost]

From what I saw yesterday around the internet is that there was concern for the label that the ESPR drug received. Even with a cheap price it may not be well received. Stock price took a hit.

Regarding NEXLETOL (bempedoic acid) - Here's the label:

NEXLETOL is an adenosine triphosphate-citrate lyase (ACL) inhibitor
indicated as an adjunct to diet and maximally tolerated statin therapy for the
treatment of adults with heterozygous familial hypercholesterolemia or
established atherosclerotic cardiovascular disease who require additional
lowering of LDL-C. (1)

Limitations of Use: The effect of NEXLETOL on cardiovascular morbidity
and mortality has not been determined. (1)

I see very little use of this drug as there is no outcome trial done yet (there is one to be reported out in 2023). - surprised it was even approved for LDL lowering with quite a few drugs out there already with some proven CV benefit